Lineage Cell Therapeutics (LCTX) Net Cash Flow Growth (1y) (2011 - 2026)
Lineage Cell Therapeutics (LCTX) Net Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,011.97 Bn | 67,011.68 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.88 Bn | 467.08 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 122.20 Bn | 114.96 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 69.93 Bn | 61.17 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.85 Bn | 50.67 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn | 53.46% |
| 10 | Lineage Cell Therapeutics | 247.48 Mn | 184.76 Mn | 1.73 Mn | -334.98% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -334.98% |
| Dec 31, 2025 | -99.07% |
| Sep 30, 2025 | 5.68% |
| Jun 30, 2025 | 57.73% |
| Mar 31, 2025 | -74.87% |
| Dec 31, 2024 | 385.80% |
| Sep 30, 2024 | 9.77% |
| Jun 30, 2024 | -174.86% |
| Mar 31, 2024 | 95.94% |
| Dec 31, 2023 | 127.93% |
| Sep 30, 2023 | 95.36% |
| Jun 30, 2023 | 359.88% |
| Mar 31, 2023 | -81.29% |
| Dec 31, 2022 | -162.25% |
| Sep 30, 2022 | -3,695.32% |
| Jun 30, 2022 | -223.65% |
| Mar 31, 2022 | -5.26% |
| Dec 31, 2021 | -6,853.33% |
| Sep 30, 2021 | -106.02% |
| Jun 30, 2021 | 94.30% |